The Ukrainian pharmaceutical company has completed clinical trials of Bioven for the treatment of pneumonia caused by the SARS-CoV-2 virus. Kostyantyn Yefimenko, head of the Biopharma board of directors, announced this on his Facebook page.
"Clinical trials of our drug Bioven (immunoglobulin) have been completed. Clinical trials began in May, 66 patients with severe disease were randomized, nine bases were involved in the study. The study was completed in October," he wrote.
According to Yefimenko, the use of Bioven in the complex therapy of pneumonia caused by coronavirus, in comparison with standard therapy, allows to achieve statistically significant advantages. In particular, a decrease in mortality by four times (from 23.6 to 6.25%), a decrease in the average time to the onset of improvement - from nine to five days, a decrease in the time required for hospitalization - by three to five days.
The head of the company noted that today 18 clinical studies of immunoglobulin are ongoing in the world. They are all started by global multinational companies, mainly in the USA and Western Europe.
According to Yefimenko, yesterday Bioven was included in the Covid-19 treatment protocol.
Earlier the head of the Verkhovna Rada committee on the health of the nation Radutsky said that the first batch of the coronavirus vaccine, which should enter Ukraine after its release, will cover 3% of the country's population.